Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVF Therapy in Acute Spontaneous Intracerebral Hemorrhage
NCT05232903Phase 1Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous adipose stromal vascular fraction in intracerebral hemorrhage (ICH) (3 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Occurrence of adverse events at 1 year. Status: unknown.
02
Drugs
autologous adipose stromal vascular fraction
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT05232903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232903.